Drugs / MH048
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04689308 | Jan 2021 → Jun 2023 | B-cell non-Hodgkin lymphoma | Minghui Pharmaceutical (Shanghai) LTD | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MH048 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04689308 ↗ |
| Route | Oral | “oral MH048 should be administered after an overnight fast.” NCT04689308 ↗ |